Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $631 | $138 | $178 | $259 |
| - Cash | $62 | $44 | $53 | $91 |
| + Debt | $50 | $40 | $7 | $0 |
| Enterprise Value | $619 | $134 | $131 | $168 |
| Revenue | $2 | $1 | $1 | $0 |
| % Growth | 41.5% | 1.5% | – | – |
| Gross Profit | $1 | -$57 | -$55 | -$0 |
| % Margin | 35% | -3,931.1% | -3,813.7% | – |
| EBITDA | -$88 | -$87 | -$81 | -$31 |
| % Margin | -4,235.9% | -5,972.8% | -5,651.5% | – |
| Net Income | -$95 | -$88 | -$81 | -$78 |
| % Margin | -4,588.8% | -5,996.7% | -5,628.3% | – |
| EPS Diluted | -1.45 | -2 | -1.9 | -3.56 |
| % Growth | 27.5% | -5.3% | 46.6% | – |
| Operating Cash Flow | -$82 | -$73 | -$76 | -$30 |
| Capital Expenditures | -$4 | -$2 | -$1 | -$1 |
| Free Cash Flow | -$86 | -$75 | -$77 | -$31 |